SAN JOSE, Calif., Dec. 11, 2019 /PRNewswire/ — Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio’s Innovatio… […]
SAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ — BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter en… […]
PALO ALTO, Calif., Dec. 10, 2019 /PRNewswire/ — Verantos, the market leader in regulatory-grade real world evidence (RWE) studies, today announced that it has received a grant from the National Institutes of Health (NIH), National Center for Advan… […]
SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ — ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that an Agency of the U.S. Federal Government has chosen ValGenesis’s cloud-based, 100% p… […]
– Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab — 48% Overall Response Rate Observed in Cerdulatinib Only; 76% Overall Response Rate Observed with Cerdulatinib in Combination with Rituximab –
SOUTH SA… […]
SAN FRANCISCO, Dec. 9, 2019 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, … […]
– Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation- Pharmacokinetic Phase 1 clinical sub-study with immediate release… […]
FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced … […]
FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced … […]
PALO ALTO, Calif., Dec. 3, 2019 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an u… […]
© 2019 San Francisco Biotechnology Network
